ArticleMetabolic brain disease2026
Effects of imbalanced gut microbial on mice with type a hepatic encephalopathy through the gut-liver-brain axis.
Article in Metabolic brain disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
BACKGROUND AND
aimsThe relationship between type A hepatic encephalopathy, a highly lethal disease, and gut microbiota remains unclear, and research on this topic is limited. The objective of our study was to investigate the correlation between an imbalance in the gut microbiota and type A hepatic encephalopathy and the impact of fecal microbiota transplantation.
methodsWe established a mouse model of gut microbiota disorder and type A hepatic encephalopathy. Feces from grades III and IV type A hepatic encephalopathy mice were transplanted into healthy mice. Antibiotic administration, intestinal symbiosis, and pathogenicity experiments were conducted. Behavioral, biochemical, pathological, 16 S rRNA gene amplicon sequencing analyses, and correlation analyses were performed.
resultsAntibiotic treatment caused a gut microbiota imbalance in mice. The degree of thioacetamide-induced type A hepatic encephalopathy was significantly aggravated after oral antibiotic administration, leading to a decline in the survival curve, accompanied by behavioral, biochemical, and pathological changes, as well as decreased Rikenellaceae levels. Transplanting feces from type A hepatic encephalopathy mice into healthy mice resulted in thioacetamide-like behavioral, biochemical, and tissue changes, as well as a significant decline in the abundance of the gut microbiota, an increase in the abundance of Prevotellaceae NK3B31, and a decrease in the abundance of Akkermansia muciniphila and Odoribacter. Additionally, significant correlations were observed between the abundances of the four intestinal microbial species and the majority of measured indicators in mice with type A hepatic encephalopathy. Notably, Akkermansia muciniphila exhibited particularly strong associations with these indicators. Although significant between-group differences were observed for Bacillus, Paenibacillus, Candidatus Saccharimonas, Escherichia-Shigella, UCG_002, Acinetobacter, and Proteus, no significant correlations were detected between these microbial taxa and any of the measured indicators.
conclusionsGut microbiota disorder aggravates lesions in thioacetamide-induced type A hepatic encephalopathy mice. Transplanting feces from mice with type A hepatic encephalopathy causes healthy mice to exhibit type A hepatic encephalopathy symptoms.
Indexed as
Identifiers
42667471What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.